COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose

As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assesse...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Journal of the neurological sciences Ročník 434; s. 120155
Hlavní autoři:	Dreyer-Alster, Sapir, Menascu, Shay, Mandel, Mathilda, Shirbint, Emanuel, Magalashvili, David, Dolev, Mark, Flechter, Shlomo, Givon, Uri, Guber, Diana, Stern, Yael, Miron, Shmuel, Polliack, Michael, Falb, Rina, Sonis, Polina, Gurevich, Michael, Achiron, Anat
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Netherlands Elsevier B.V 15.03.2022
Témata:	Acute relapse Adult Adverse events Antibodies, Viral BNT162 Vaccine COVID-19 COVID-19 - prevention & control COVID-19 Vaccines - adverse effects Humans Immune response Multiple sclerosis Multiple Sclerosis - drug therapy Neurology SARS-CoV-2 Third booster dose Vaccination Vaccination - adverse effects COVID-19 Third booster dose Multiple sclerosis Immune response Adverse events Vaccination Acute relapse
ISSN:	0022-510X, 1878-5883, 1878-5883
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!